How big is Sutro Biopharma, Inc.?

As of Jun 18, Sutro Biopharma, Inc. has a market capitalization of 66.73 million, with net sales of 66.44 million and a net profit of -245.22 million over the last four quarters. The company's shareholder's funds are 44.60 million, and total assets are 387.21 million.

Market Cap: As of Jun 18, Sutro Biopharma, Inc. has a market capitalization of 66.73 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Sutro Biopharma, Inc. reported net sales of 66.44 million and a net profit of -245.22 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 44.60 million, while total assets were reported at 387.21 million.

What does Sutro Biopharma, Inc. do?

Sutro Biopharma, Inc. is a clinical stage company focused on developing protein therapeutics for cancer and autoimmune disorders. As of March 2025, it reported net sales of $17 million and a net loss of $76 million, with a market cap of $66.73 million.

Overview:<BR>Sutro Biopharma, Inc. is a clinical stage drug discovery, development, and manufacturing company focused on creating protein therapeutics for cancer and autoimmune disorders within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 17 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -76 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 66.73 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.97 <BR>Return on Equity: 887.14% <BR>Price to Book: -2.59 <BR><BR>Contact Details:<BR>Address: 310 Utah Ave Ste 150, SOUTH SAN FRANCISCO CA: 94080-6803 <BR>Tel: 1 650 3928412 <BR>Fax: 1 302 6555049 <BR>Website: http://www.sutrobio.com/

Should I buy, sell or hold Sutro Biopharma, Inc.?

Who are in the management team of Sutro Biopharma, Inc.?

As of March 2022, the management team of Sutro Biopharma, Inc. includes Chairman Connie Matsui, CEO William Newell, and Directors James Panek, Daniel Petree, Jon Wigginton, Michael Dybbs, and John Freund. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Sutro Biopharma, Inc. includes the following individuals:<BR><BR>- Ms. Connie Matsui, Chairman of the Board<BR>- Mr. William Newell, Chief Executive Officer and Director<BR>- Mr. James Panek, Director<BR>- Mr. Daniel Petree, Director<BR>- Dr. Jon Wigginton, Director<BR>- Dr. Michael Dybbs, Independent Director<BR>- Dr. John Freund, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is Sutro Biopharma, Inc. overvalued or undervalued?

As of March 18, 2021, Sutro Biopharma, Inc. is considered overvalued and risky due to significant financial distress, reflected in poor valuation metrics and a year-to-date stock decline of 50.93%, compared to the S&P 500's positive return of 12.22%.

As of 18 March 2021, the valuation grade for Sutro Biopharma, Inc. moved from fair to risky, indicating a deteriorating outlook. The company is overvalued based on its current financial metrics, which include a Price to Book Value of -2.77, an EV to EBIT of -0.09, and an EV to EBITDA of -0.09, all suggesting significant financial distress. In comparison to peers, Sutro's valuation ratios are notably worse; for instance, Akebia Therapeutics, Inc. has a P/E ratio of -30.59, while scPharmaceuticals, Inc. shows an EV to EBITDA of -4.64.<BR><BR>Recent stock performance further underscores this valuation concern, with Sutro Biopharma's year-to-date return at -50.93%, significantly lagging behind the S&P 500's positive return of 12.22%. Over the past year, Sutro has declined by 77.14%, while the S&P 500 has gained 17.14%, reinforcing the notion that the stock is currently overvalued.

Is Sutro Biopharma, Inc. technically bullish or bearish?

As of September 12, 2025, Sutro Biopharma's technical trend is neutral with mixed signals, showing a year-to-date return of -50.93% compared to the S&P 500's 12.22%.

As of 12 September 2025, the technical trend for Sutro Biopharma, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows a bullish signal on the monthly but no signal on the weekly. Bollinger Bands indicate a bullish stance weekly but mildly bearish monthly. Moving averages are mildly bearish on a daily basis, and the KST presents a bullish signal weekly but bearish monthly. Dow Theory shows a mildly bearish weekly trend and a mildly bullish monthly trend. OBV is mildly bullish across both time frames.<BR><BR>In terms of performance, Sutro Biopharma has significantly underperformed compared to the S&P 500, with a year-to-date return of -50.93% versus the S&P 500's 12.22%, and a one-year return of -77.14% compared to 17.14% for the benchmark.